
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Clinical Management of NSCLC With Bone Metastases
Case: A 62-Year-Old Man With NSCLC and Bone Metastases


